With the long-awaited global commercialization of lazertinib, Oscotec Inc. and its US subsidiary Genosco, the originators of the novel lung cancer drug, are poised to see a steady inflow of revenues rarely seen at South Korean bioventures.
To gear up for the next phase of expected growth, Oscotec brought in Taeyoung Yoon, former head of the research...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?